Serum concentration of cardiac Troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes.
暂无分享,去创建一个
V. Pitini | S. Coglitore | D. Azzarello | C. Arrigo | M. Righi | G. La Gattuta | C. Amata
[1] E. Baxter,et al. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. , 2003, Blood.
[2] K. Kataoka,et al. Persistently Increased Serum Concentrations of Cardiac Troponin T in Patients With Idiopathic Dilated Cardiomyopathy Are Predictive of Adverse Outcomes , 2001, Circulation.
[3] J. Seward,et al. Clinical and echocardiographic features of hypereosinophilic syndromes. , 2000, The American journal of cardiology.
[4] A. Matsumori,et al. Measurement of serum concentrations of cardiac troponin T in patients with hypereosinophilic syndrome: a sensitive non-invasive marker of cardiac disorder. , 2000, Internal medicine.
[5] C. Wheatley,et al. Activation of platelets by eosinophil granule proteins , 1990, The Journal of experimental medicine.